Commerzbank Ag set a €124.00 ($144.19) price objective on Bayer AG (FRA:BAYN) in a research report sent to investors on Thursday, October 26th. The brokerage currently has a buy rating on the healthcare company’s stock.
BAYN has been the subject of several other research reports. Sanford C. Bernstein set a €128.00 ($148.84) target price on shares of Bayer AG and gave the company a buy rating in a research report on Friday, July 7th. J P Morgan Chase & Co reiterated a buy rating on shares of Bayer AG in a research report on Tuesday, August 29th. HSBC Holdings plc set a €105.00 ($122.09) target price on shares of Bayer AG and gave the company a neutral rating in a research report on Tuesday, August 29th. Citigroup Inc. set a €128.00 ($148.84) price objective on shares of Bayer AG and gave the company a buy rating in a research report on Monday, July 24th. Finally, Nord/LB set a €106.00 ($123.26) price objective on shares of Bayer AG and gave the company a neutral rating in a research report on Friday, July 28th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating and thirteen have issued a buy rating to the company’s stock. The company presently has a consensus rating of Buy and an average price target of €122.48 ($142.41).
Shares of Bayer AG (BAYN) traded down €0.90 ($1.05) during trading hours on Thursday, hitting €109.80 ($127.67). 2,252,260 shares of the company’s stock were exchanged. Bayer AG has a 52 week low of €85.72 ($99.67) and a 52 week high of €123.82 ($143.98).
COPYRIGHT VIOLATION WARNING: “Bayer AG (FRA:BAYN) PT Set at €124.00 by Commerzbank Ag” was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. & international copyright and trademark laws. The legal version of this news story can be read at https://www.dispatchtribunal.com/2017/11/12/bayer-ag-bayn-given-a-124-00-price-target-at-commerzbank-ag.html.
About Bayer AG
Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, Crop Science, Animal Health, and Covestro segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and womens health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
Receive News & Ratings for Bayer AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer AG and related companies with MarketBeat.com's FREE daily email newsletter.